Virtual Library

Start Your Search

Natália Carvalho



Author of

  • +

    FP02 - Health Services Research/Health Economics (ID 120)

    • Event: WCLC 2020
    • Type: Posters (Featured)
    • Track: Health Services Research/Health Economics
    • Presentations: 1
    • Moderators:
    • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
    • +

      FP02.06 - Implementation of a Lung Cancer Value-Based Care Framework in a Low and Middle-Income Country Institution (ID 3338)

      00:00 - 00:00  |  Author(s): Natália Carvalho

      • Abstract
      • Slides

      Introduction

      Assessment of the value of lung cancer treatment, and the performance of institutions delivering care is critical, especially in low and middle-income countries, with limited resources. To fully implement measures that support a value-based approach, cancer care institutions must comply with real-world registries with standardized outcomes. Herein, we present the first report of a prospective study to assess non-small cell lung cancer (NSCLC) patient-centered outcomes based on the International Consortium for Health Outcome Measurements (ICHOM) standard set.

      Methods

      This is a prospective, observational study of NSCLC patients treated at a nationwide private cancer care institution in Brazil between July 2014 and December 2019. The EORTC QLQ-C30 and QLQ-LC13 questionnaires were applied at established time points to analyze the disease burden on patients’ health status, serial changes throughout treatment, and prognostic impact.

      Results

      This first report comprises 337 patients, from a single institution; most patients were males (57.0%), white (64.7%), and smokers (81.3%). Adenocarcinoma was the most prevalent histological subtype (70.9%), and most patients presented with advanced disease (stages III/IV in 80.7%). Chemotherapy was recommended in 276 patient cases (81.9%), targeted therapy in 49 patients (14.6%), and immunotherapy in only 113 (33.5%). Median OS was 22.2 months (95% CI, 15.8-28.8), and 2-year OS for stages III and IV were 53.4% and 28.0%, respectively. EORTC QLQ-LC13 and QLQ-C30 questionnaires were responded by 333 (98%) and 290 (86%) patients at baseline, and by 225 (67%) and 192 (57%) at third evaluation. Advanced stage was associated with higher symptom burden - fatigue (p=0.03), pain (p<0.001), arm pain (p=0.022) - and worse global, social, and physical functioning (all p<0.001). Males (p<0.001), with older age (p<0.001) and more comorbidities (p<0.001) had higher emotional scores. Upon serial comparisons of quality of life (QoL) parameters during the first 2 years, most factors evolved to either improvement or stability. Cough (p=0.02), pain (p=0.002), global (p<0.001), and emotional (p<0.001) functioning showed significant improvement over time. Staging (p<0.001) and fatigue (p=0.001) were independently associated with OS.

      Conclusion

      Our results demonstrate the feasibility of a prospective lung cancer registry based on an international standardized dataset focused on patient-reported outcomes. QoL parameters impacted on NSCLC outcomes and can be a tool to align care delivery, increasing access and quality of cancer care across different institutions in low and middle-income countries.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.